St. Johns Investment Management Company buys $1,330,651 stake in Amgen (AMGN)

Amgen (AMGN) : St. Johns Investment Management Company scooped up 93 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 19, 2016. The investment management firm now holds a total of 8,151 shares of Amgen which is valued at $1,330,651.Amgen makes up approximately 1.16% of St. Johns Investment Management Company’s portfolio.

Other Hedge Funds, Including , Evanson Asset Management added AMGN to its portfolio by purchasing 1,388 company shares during the most recent quarter which is valued at $226,591. Amgen makes up approx 0.07% of Evanson Asset Management’s portfolio.Stewart Patten Co reduced its stake in AMGN by selling 41 shares or 0.66% in the most recent quarter. The Hedge Fund company now holds 6,212 shares of AMGN which is valued at $1,014,109. Amgen makes up approx 0.19% of Stewart Patten Co’s portfolio.First Manhattan Co reduced its stake in AMGN by selling 945 shares or 0.36% in the most recent quarter. The Hedge Fund company now holds 265,054 shares of AMGN which is valued at $43,185,248. Amgen makes up approx 0.26% of First Manhattan Co’s portfolio. Investment Partners Ltd Oh Adv sold out all of its stake in AMGN during the most recent quarter. The investment firm sold 2,114 shares of AMGN which is valued $339,339.

Amgen opened for trading at $162.45 and hit $163.65 on the upside on Wednesday, eventually ending the session at $163.25, with a gain of 0.47% or 0.76 points. The heightened volatility saw the trading volume jump to 21,61,425 shares. Company has a market cap of $122,636 M.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.